AAP
TNYA icon

Arax Advisory Partners’s Tenaya Therapeutics TNYA Stock Holding History

Arax Advisory Partners’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60
Closed -$97 – 4523
2025
Q3 		$97 Buy
+60
New +$60 ﹤0.01% 3500
2024
Q4 		– Sell
-105
Closed -$203 – 2745
2024
Q3 		$203 Hold
105
– – ﹤0.01% 2512
2024
Q2 		$326 Buy
+105
New +$434 ﹤0.01% 2388

Other funds holding TNYA

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Arax Advisory Partners's TNYA Position: Q4 2025 in Review

Arax Advisory Partners sold out of Tenaya Therapeutics (TNYA) in Q4 2025, closing a stake of 60 shares — an estimated $97 sold.

Arax Advisory Partners first reported a position in TNYA in Q2 2024 and held it in 3 quarters. The position peaked at $326 in Q2 2024. 97 funds tracked by Wall St. Rank hold TNYA as of Q4 2025.

  • Arax Advisory Partners reported no remaining Tenaya Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 60 Tenaya Therapeutics shares in Q4 2025, an estimated $97.
  • Arax Advisory Partners first reported a position in Tenaya Therapeutics in Q2 2024 and held it in 3 quarters.
  • Arax Advisory Partners's Tenaya Therapeutics position peaked at $326 in Q2 2024.
  • 97 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.